Poolbeg Pharma Secures European Patent for Promising Immunomodulator
Poolbeg Pharma has strengthened its intellectual property position in immunology and cancer immunotherapy with the news that the European Patent Office has granted its European Immunomodulator II patent application for POLB 001, a treatment candidate targeting severe influenza and other serious conditions.
The clinical-stage biopharmaceutical company, which is focused on advancing cancer immunotherapy and immune-modulating therapies, said the newly granted patent covers the use of POLB 001, a selective p38 MAP kinase (MAPK) inhibitor.
This mechanism of action has shown strong potential across several high-need disease areas, most notably in the prevention and treatment of cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and in severe influenza.
Cytokine Release Syndrome, a potentially life-threatening complication associated with certain cancer immunotherapies, represents a particularly significant commercial and clinical opportunity.
Poolbeg noted that the market for CRS prevention and treatment linked to cancer immunotherapy is estimated to be worth over US$10 billion, underscoring the scale of the opportunity for POLB 001 if its development continues to progress successfully.
In parallel, severe influenza remains a persistent global health threat, creating additional demand for innovative, host-targeted therapies.
The company confirmed that it is actively expanding its global intellectual property portfolio, and that this latest European patent grant further consolidates its position. By securing patent protection for POLB 001 across multiple disease indications, Poolbeg believes it is enhancing both the long-term value of the asset and its appeal to potential pharmaceutical partners.
Commenting on the news, Poolbeg Pharma’s Chief Executive Officer said that the patent grant from the European Patent Office highlights the strong progress the company continues to make in developing and strengthening its IP portfolio for POLB 001.
They added that the expanded protection across several important disease indications further enhances the value and attractiveness of POLB 001 for potential collaborators and licensees.
Poolbeg’s broader IP strategy is built around patents that cover the use of p38 MAPK inhibitors in patients with severe influenza, as well as in the prevention and treatment of CRS caused by cancer immunotherapy.
POLB 001 sits at the centre of this strategy. Although still in development, the candidate is positioned as a potential answer to significant unmet needs in global healthcare, particularly in areas where managing the immune response safely and effectively is critical to patient outcomes.
Final Thoughts:
Taken together, the European patent grant, the company’s expanding IP estate, and the broad therapeutic promise of POLB 001 mark another important step forward for Poolbeg Pharma.
As it continues to refine and protect its pipeline, the company is aiming to transform the cancer immunotherapy landscape and deliver innovative treatments for serious conditions where current options remain limited.
News Credits: Poolbeg granted European patent for POLB 001
Things you may also like:
- Eisai Unveils New Long-Term Data on Lecanemab in Early Alzheimer’s Disease
- Jones Village Bakery Fires Up £20 Million Production Line in Major Expansion Drive
- CNX Therapeutics Acquires Global Sativex Business from Jazz